期刊
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
卷 40, 期 2, 页码 200-207出版社
WILEY
DOI: 10.1111/apt.12800
关键词
-
资金
- Danisco
- General Mills, Inc.
- Procter Gamble
- Salix Inc.
- NIH [K23 DK075621, RO3 DK084294, RO1DK047700, RO1DK073338, F30DK085906, RO1 PA 10-067]
- Danone, Prometheus
- Zimmer, Inc.
- Philips Oral Health Care, Inc.
- Ono Pharmaceuticals
- Ironwood Pharmaceuticals
- Takeda Pharmaceuticals NIDDK
- NCAAM
- AHRQ
- Takeda Pharmaceuticals
- NIDDK [K01 DK092330]
Background In a recent double-blinded clinical trial, the probiotic combination of Lactobacillus acidophilus NCFM (L-NCFM) and B-LBi07 reduced bloating symptoms in patients with functional bowel disorders; an effect more evident in those who reported abdominal pain. In mice, L-NCFM but not B-LBi07 induced colonic mu-opioid receptor (MOR) and cannabinoid receptor 2 (CB2) expression, and reduced visceral sensitivity. Aims To determine if L-NCFM was the active component in the clinical trial and to investigate the mechanism of action in humans with mild to moderate abdominal pain. Methods Caucasian women (n=20) 18-70years with mild to moderate abdominal pain were enrolled in a double-blind, two-armed, single-centre study. Patients were given either L-NCFM alone or in combination with B-LBi07 for 21days at a total dose of 2x1010CFU b.d. Colonic biopsies were collected during unsedated, unprepped flexible sigmoidoscopy before and at the end of probiotic consumption. mRNA and immunostaining were then performed on these biopsies. Patients kept symptom diaries for the 7days prior to starting probiotic therapy and for the last 7days of therapy. Results L-NCFM alone, but not with B-LBi07, induced colonic MOR mRNA and protein expression, as well as downstream signalling, as measured by enterocyte STAT3-phosphorylation. In contrast, CB2 expression was decreased. Both treatment groups trended towards improvement in symptoms, but the study was insufficiently powered to draw meaningful conclusions. Conclusions Lactobacillus acidophilus NCFM modulates mu-opioid receptor expression and activity, while the combination of L-NCFM and B-LBi07 does not. This study provides a possible mechanism for action by which probiotics modulates pain sensation in humans (Clinical Trial Number: NCT01064661).
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据